10-Q: Inhibrx Biosciences Q2 2026: Clinical Progress Amidst Financial Strain

Inhibrx Biosciences reported continued progress in its clinical pipeline for ozekibart and INBRX-106, alongside a significant increase in long-term debt and ongoing net losses for the second quarter of 2026.

Summary

• Inhibrx Biosciences reported a net loss of $36.7 million for the three months ended June 30, 2026, compared to a net loss of $28.7 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was $70.1 million, compared to $72.0 million in the prior year.
• Total revenue for the three and six months ended June 30, 2026, was $0, a decrease from $1.3 million in the prior year periods, which was attributed to license fee revenue from the Scithera License Agreement.
• Research and development expenses increased by 7% to $23.9 million for the three months ended June 30, 2026, and decreased by 17% to $49.1 million for the six months ended June 30, 2026.
• General and administrative expenses increased by 28% to $8.3 million for the three months ended June 30, 2026, and by 12% to $14.0 million for the six months ended June 30, 2026.
• Long-term debt increased significantly to $176.3 million as of June 30, 2026, from $100.6 million as of December 31, 2025, primarily due to the Term B Loans funded under the Amended 2025 Loan Agreement.
• Cash and cash equivalents stood at $133.3 million as of June 30, 2026, which the company believes is sufficient to fund operations for at least the next 12 months.
• The company announced positive interim data for ozekibart in colorectal cancer and met the primary endpoint for PFS in a chondrosarcoma trial, with the FDA accepting its BLA for ozekibart.
• Positive interim results were also reported for INBRX-106 in combination with pembrolizumab for head and neck squamous cell carcinoma.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to continued net losses, increasing debt, and the absence of revenue in the current period, despite promising clinical trial updates.

Positives

• Ozekibart demonstrated a 20% ORR in combination with FOLFIRI for colorectal cancer, significantly higher than the historical standard of care (1-6%).
• Ozekibart achieved a 52% reduction in the risk of disease progression or death in chondrosarcoma patients compared to placebo, more than doubling median PFS.
• The FDA accepted Inhibrx's biologics license application (BLA) for ozekibart in conventional chondrosarcoma.
• INBRX-106 in combination with pembrolizumab showed a 44.0% confirmed objective response rate in first-line HNSCC, compared to 21.4% for pembrolizumab alone.
• Three complete responses were observed with the INBRX-106 combination in HNSCC, indicating tumor clearance.
• The company believes its existing cash and cash equivalents of $133.3 million are sufficient to fund operations for at least the next 12 months.
• The company secured an additional $75.0 million in funding through the March 2026 Amendment to its loan agreement.
• A subsequent event disclosed a Second Amendment to the loan agreement on July 15, 2026, providing for up to an additional $325.0 million in gross proceeds, with $100.0 million funded upon execution.

Negatives

• The company reported a net loss of $36.7 million for the three months ended June 30, 2026, an increase from the prior year's loss of $28.7 million.
• Total revenue for the three and six months ended June 30, 2026, was $0, down from $1.3 million in the comparable periods of 2025.
• Long-term debt increased substantially to $176.3 million as of June 30, 2026, from $100.6 million at the end of 2025.
• Research and development expenses increased by 7% to $23.9 million for the three months ended June 30, 2026, indicating ongoing significant investment.
• General and administrative expenses increased by 28% to $8.3 million for the three months ended June 30, 2026.
• The company has an accumulated deficit of $316.3 million as of June 30, 2026.
• The company expects to continue incurring significant losses for the foreseeable future.
• The company plans to finance future cash needs through equity offerings or debt financings, which could dilute existing stockholders or impose restrictive covenants.

Risks

• The company depends heavily on the success of its therapeutic candidates, which are in various stages of development and may fail or suffer delays.
• There is no assurance that ozekibart will gain U.S. regulatory approval on the expected timeline or at all, as the FDA may require additional trials or data.
• Form 483 observations were issued to the company and clinical investigators during FDA inspections related to the BLA review for ozekibart, which could cause delays.
• Clinical and preclinical development is expensive, lengthy, and uncertain, with a high historical failure rate.
• Failure can occur at any stage of development, and future clinical trial results may not be successful.
• The company may not have the financial resources to continue development if trials are delayed or terminated.
• Delays in clinical trials can increase costs, slow down the approval process, and jeopardize the ability to commence product sales.
• If ozekibart receives approval, there is no guarantee of successful commercialization due to potential issues with sales, marketing, distribution, reimbursement, or market acceptance.

Future Outlook

The company believes its existing cash and cash equivalents are sufficient to fund operations for at least the next 12 months. However, it anticipates continued net losses and expects to require substantial additional capital in the future through equity offerings, debt financings, or strategic collaborations to fund its ongoing development programs and potential commercialization efforts.

Management Comments

• We believe that our existing cash and cash equivalents will be sufficient to fund the Companys operations for at least 12 months from the date these consolidated financial statements are issued.
• The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements.
• We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development and support our preclinical programs.
• We will need substantial additional capital in the future to support these efforts.
• Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date of filing of this Quarterly Report.

Industry Context

StockSavvy.ai notes that Inhibrx Biosciences operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, where significant investment in R&D is required to advance drug candidates through trials. The company's focus on oncology and its use of proprietary protein engineering platforms align with current industry trends aiming for more targeted and effective therapies. The substantial increase in debt and the ongoing need for capital are common challenges for companies at this stage, especially those pursuing novel biologics.

Comparison to Industry Standards

• The reported ORR of 20% for ozekibart in combination with FOLFIRI for colorectal cancer is notably higher than the historical standard of care (1-6% ORR per RECIST v1.1), suggesting a potentially competitive efficacy profile.
• The PFS benefit demonstrated by ozekibart in chondrosarcoma (5.52 months vs. 2.66 months for placebo) is significant, especially given the lack of approved systemic options for this disease, positioning it as a potential first-in-class therapy.
• The ORR of 44.0% for INBRX-106 plus pembrolizumab in first-line HNSCC compares favorably to typical response rates for PD-1 inhibitors alone in similar patient populations, indicating a potential synergistic benefit.
• The company's R&D expenses as a percentage of total operating expenses remain high, which is typical for clinical-stage biopharmaceutical companies investing heavily in pipeline development. For the three months ended June 30, 2026, R&D was approximately 74% of total operating expenses ($23.9M/$32.1M).

Legal Proceedings

• The company is not party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Creditors and lenders may be impacted by the company's increasing debt levels and its reliance on future financing.
• Employees may be affected by the company's continued losses and the need for potential future cost reductions or reallocations of resources.
• Suppliers may face extended payment terms if the company is unable to secure adequate funding.

Next Steps

• Meet with the FDA in Q4 2026 to discuss plans for a first-line registrational trial in CRC and potential accelerated regulatory pathway for ozekibart in fourth-line CRC.
• Announce interim results from two additional Phase 1 cohorts in CRC (combination with Folfiri and Avastin; combination with Lonsurf and Avastin) during Q1 2027.
• Complete enrollment in the Phase 1/2 trial of ozekibart in Ewing sarcoma in 2027.
• Begin the Phase 3 portion of the HexAgon study (INBRX-106) during Q3 2026.
• Initiate a study of INBRX-106 in the perioperative setting in NSCLC.
• Explore combinations of INBRX-106 with agents such as vaccines, T-cell engagers, and CAR-Ts.
• The company expects to no longer be an emerging growth company effective December 31, 2026.
• The company expects to no longer be a smaller reporting company beginning with its Quarterly Report for the period ending March 31, 2027.

Key Dates

Recommendation

The company shows promising clinical development for its lead candidates, ozekibart and INBRX-106, with positive data and regulatory milestones achieved. However, the significant increase in debt, continued substantial net losses, and the absence of revenue in the current period present considerable financial risk. The substantial capital raise announced post-quarter end mitigates some immediate liquidity concerns but introduces dilution risk. Therefore, a 'hold' recommendation is appropriate, balancing clinical progress against financial realities.

Keywords

biopharmaceutical, clinical-stage, oncology, ozekibart, INBRX-106, drug development, FDA, BLA